相关实验视频
Updated: Jul 16, 2026
04:28
Lung Tumor Cell Recruitment Assay
Published on: February 26, 2019
5.3K
根据世卫组织的说法,小肺腺癌的侵袭性可重复性研究和经过修改的分类,得到生物标志物的支持
Erik Thunnissen1, Hans Blaauwgeers2, Federica Filipello3
1Dept. of Pathology, Amsterdam UMC, VU University, Amsterdam, the Netherlands.
Lung cancer (Amsterdam, Netherlands)
|January 10, 2025
概括
对非性肺腺癌 (NMA) 的修改分类显示了比世卫组织标准更高的可复制性. 这种改进的分类更好地识别非侵入性,低风险的病变,得到生物标志物分析的支持.
科学领域:
- 肺部病理学 肺部病理学
- 在瘤学瘤学.
- 癌症的分期 癌症的分期
背景情况:
- 肺腺癌的精确分期对于患者的治疗和预后至关重要.
- 目前世界卫生组织 (WHO) 对非性腺癌 (NMA) 的分类在持续评估瘤入侵方面面临挑战.
- 区分侵袭性和非侵袭性NMA对于精确的pT分期至关重要.
研究的目的:
- 为了比较当前的世卫组织分类与修改后的NMA分类的可重复性.
- 评估修改后的分类在识别非侵入性,低风险NMA病变方面的有效性.
- 评估直角生物标记分析在支持修改后的分类中的实用性.
主要方法:
- 一个回顾性病例控制研究,对70个小NMA pT1N0M0病例进行了5年的随访.
- 通过42名肺病理学家对病例的审查,使用WHO和修改后的分类三轮.
- 对直角生物标志物分析,包括增殖率,瘤突变负担和转录基因特征.
主要成果:
- 对侵入性的可复制性 (卡帕值) 在经过三轮 (0.27到0.62) 的修改分类后显著改善.
- 与世卫组织分类相比,修改后的分类减少了pT分期的变化.
- 生物标志物分析支持通过修改后的分类识别的侵袭性和非侵袭性病例之间的区别.
结论:
- 修改后的NMA分类比目前的世卫组织分类提供了更好的可重复性.
- 这种修改后的方法有效地识别出完全非侵入性,低风险的NMA病变.
- 生物标记数据证实了修改后的分类对改善肺癌分期的临床实用性.
相关概念视频
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...